The goals of the Leukemia Fellowship Program are to train competent, qualified, caring and empathic physicians who are mindful of the significance of their role in the diagnosis and management of patients with the acute and chronic leukemias as well as myelodysplastic syndromes and myeloproliferative disorders.
The 1- or optional 2-year program is geared toward a preparation of independent and competent management of patients with all of these disorders. The program is dedicated to training physicians who will effectively work in the current and future health care systems.
The Department of Leukemia at MD Anderson endorses a team approach to patient care, while recognizing that fellows must have opportunities for individual critical decision-making and patient responsibility as defined by the Texas Medical Board.
The Leukemia Fellowship Program accepts applications for positions August 1 through November 1. The Program accepts up to ten new fellows per year. Initially, a one-year commitment to the Program is required. Fellows in their first year may be considered for an additional year at their request.
The Leukemia Fellowship is non-standard and commences July 1 through June 30 and is recognized by the Texas Medical Board as an approved fellowship program. The program It is affiliated with The University of Texas MD Anderson Cancer Center’s Hematology/Oncology Fellowship which is accredited by ACGME.
Guillermo Garcia-Manero, M.D.
Training Program Director
Tapan M. Kadia, M.D.
Associate Training Program Director
Nicole Bowes, Ph.D.
Program Director, Educational Programs
Hagop M. Kantarjian, M.D.
Mary E. Silverstein
For general inquires please send email to firstname.lastname@example.org.
The Program achieves its goals through a combination of inpatient and outpatient clinical experiences. The ACGME core competencies and milestones are achieved through a required set of rotations, a didactic curriculum and elective rotations designed to broaden the base of knowledge. The Fellowship complements the hands on training with an even broader range of conferences that are available through national and international hematology and medical oncology organizations. Fellows are involved in clinical research and are encouraged to develop a research program of his/her own and to compete for national presentations and awards.
The recent achievements of our Program describes an undeniable understanding just how valuable it is to provide in-depth clinical training in the diagnosis and management of leukemia and related malignant disorders (MDS, MPN), and to provide clinical and research training in acute leukemia.
During the first year of fellowship is designed to orient the trainee to the diseases and treatments commonly encountered in leukemia. This intense, hands-on training includes outpatient clinics where the fellow serves as the primary oncologist for the patient, and benefits from close precepting. Fellows are expected to learn about each case from all available resources, including literature and faculty experts. During this time, the fellow also rotates through leukemia inpatient wards to gain focused exposure to specific disease types.
During the optional second year of training, the fellow continues to expand his or her general clinical education through outpatient clinic, inpatient consults and specialty projects. In addition to the clinical responsibilities, fellows begin to focus on a narrow subspecialty, both clinically and in research.
Individuals applying for admissions into the Leukemia Fellowship Program must hold either a M.D./D.O. degree or its foreign equivalent along with a valid certificate from the Educational Commission for Foreign Medical Graduates (ECFMG). Applicants must be able to obtain and maintain a Texas Training Permit, required by the Texas State Board of Medical Examiners, and maintain appropriate visa status. Individuals who are interested in applying must have completed three (3) years of internal medicine training by the start of the program which begins July 1.
The deadline for submission of applications for the 2020-2021 Academic Year will be November 1, 2019. Interviews will tentatively be conducted throughout the Academic Year. The application checklist provides additional information on required documents.
Applications are accepted through the DISCOVER application system.
All required documents must be sent by postal or express mail to:
Leukemia Fellowship Program
The University of Texas MD Anderson Cancer Center
Department of Leukemia
1515 Holcombe Blvd., Unit 428
Houston, TX 77030
For additional inquiries, contact:
Nicole Bowes, Ph.D.
Leukemia Educational Programs
MD Anderson Cancer Center is committed to encouraging good health and staying true to our mission to end cancer. If you are applying for a GME fellowship or residency program starting on or after July 1, 2016, please be advised that MD Anderson will have instituted a tobacco-free hiring process as part of its efforts to achieve these goals. If you are offered an appointment, you will be subject to a Pre-Employment Drug Screen for tobacco compounds in compliance with applicable state laws. If you do not pass the urine drug screening which includes testing for tobacco compounds, you CANNOT be appointed at MD Anderson. Should you fail to meet this contingency, MD Anderson will withdraw your offer of appointment for the academic year. You may reapply for the following academic year, but there are no guarantees that you will be offered a position as many of our programs are already filled for several years out.